Pressor and renal hemodynamic effects of the novel angiotensin a peptide are angiotensin II type 1A receptor dependent

Hypertension

Volumn 57, Issue 5, 2011, Pages 956-964

  Yang, Rui ^a   Smolders, Ilse ^a   Vanderheyden, Patrick ^a   Demaegdt, Heidi ^a   Van Eeckhaut, Ann ^a   Vauquelin, Georges ^a   Lukaszuk, Aneta ^a   Tourwé, Dirk ^a   Chai, Siew Yeen ^b   Albiston, Anthony L ^c   Nahmias, Clara ^d,e,f   Walther, Thomas ^g,h   Dupont, Alain G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d INSTITUT COCHIN   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF HULL   (United Kingdom)

^h JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

angiotensin A; angiotensin II; AT1 receptors; AT2 receptors; blood pressure; renal blood flow

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1A RECEPTOR; ANGIOTENSIN A PEPTIDE; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; CANDESARTAN; COMPOUND 21; FENOLDOPAM; HYPERTENSIVE FACTOR; NICOTINOYLTYROSYL(N BENZYLOXYCARBONYLARGINYL)LYSYLHISTIDYLPROLYLISOLEUCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY ARTERY VASOCONSTRICTION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; MALE; MICRODIALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; TRANSGENIC MOUSE; VASOCONSTRICTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINS; ANIMALS; BENZIMIDAZOLES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION; KIDNEY; MALE; MICE; MICE, KNOCKOUT; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL CIRCULATION; STATISTICS, NONPARAMETRIC; TETRAZOLES; VASOCONSTRICTION;

EID: 79955479435     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.161836     Document Type: Article

References (20)

1. Carey RM, Padia SH. Angiotensin AT2 receptors: control ofrenal sodium excretion and blood pressure. Trends Endocrinol Metab. 2008;19:84-87. (Pubitemid 351442917)
2. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology: XXIII-the angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
3. Miserey S, Clauser E. Angiotensin II receptors: classification, structure, and signal transduction. Therapie. 1998;53:205-211. (Pubitemid 28337003)
4. Ardaillou R, Chansel D. Synthesis and effects of active fragments of angiotensin II. Kidney Int. 1997;52:1458-1468. (Pubitemid 28032049)
5. Jankowski V, Vanholder R, van der Giet M, Tölle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schlüter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J. Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol. 2007;27: 297-302. (Pubitemid 46143043)
6. Badejo A Jr, Greco AJ, Casey DB, Cook JL, Murthy SN, Kadowitz PJ. Analysis of hemodynamic responses and the proliferative effect of the novel angiotensin peptide angiotensin A. FASEB J. April 23, 2009 (Meeting Abstract Supplement) 935.2. http://www.fasebj.org/cgi/content/meeting-abstract/23/1- MeetingAbstracts/935.2. Accessed March 17, 2011.
7. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem. 2001;276:48623-48626.
8. 1a-receptor mediated. J Hypertens. 2010; 28:487-494.
9. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008. (Pubitemid 39507341)
10. Verheijen I, Fierens FL, Debacker JP, Vauquelin G, Vanderheyden PM. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type1 receptors. Fund Clin Pharmacol. 2000;14:577-585. (Pubitemid 32052554)
11. Schuijt MP, Saxena PR, Danser AH. No net effect of angiotensin II on blood pressure? Hypertension. 2002;39:E27-E28.
12. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142: 821-830. (Pubitemid 38998096)
13. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709-716.
14. Gelosa P, Pignieri A, Fandriks L, de Gasparo M, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens. 2009;27:2444-2451.
15. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748-750.
16. Tanaka M, Tsuchida S, Imai T, Fujii N, Miyazaki H, Ichiki T, Naruse M, Inagami T. Vascular response to angiotensin II is exaggerated through an upregulation of AT1 receptor in AT2 knockout mice. Biochem Biophys Res Commun. 1999;258:194-198. (Pubitemid 29287026)
17. Le MT, Vanderheyden PM, Szaszak M, Hunyady L, Vauquelin G. An-giotensin IV is a potent agonist for constitutive active human AT1 receptors: distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem. 2002;277:23107-23110. (Pubitemid 34952133)
18. Capponi AM, Catt KJ. Angiotensin II receptors in adrenal cortex and uterus: binding and activation properties of angiotensin analogues. J Biol Chem. 1979;254:5120-5127. (Pubitemid 9227466)
19. Khosla MC, Smeby RR, Bumpus FM. Structure-activity relationship in angiotensin II analogs. In: Page IH, Bumpus FM, eds. Angiotensin. New York, NY: Springer-Verlag; 1974:128.
20. Lanckmans K, Stragier B, Sarre S, Smolders I, Michotte Y. Nano-LC-MS/MS for the monitoring of angiotensin IV in rat brain microdia-lysates: limitations and possibilities. J Sep Sci. 2007;30:2217-2224. (Pubitemid 47497022)